China's Supreme People's Court Upholds Novo Nordisk's Semaglutide Patent, Reinforcing IP Protection For Wegovy, Ozempic And Rybelsus

Today, the Supreme People's Court in China made a positive decision concerning the intellectual property rights relating to the semaglutide compound patent. Novo Nordisk is pleased that the Court has upheld the Beijing IP Court ruling recognising the validity of the semaglutide compound patent.



"This outcome is very positive for semaglutide and demonstrates firm government support for protecting medical innovation," said Mike Doustdar, president and CEO of Novo Nordisk. "This decision also strengthens confidence for foreign companies' sustainable development in China and will motivate further development and introduction of innovative medicines for the benefit of patients."

Semaglutide is a novel, long-acting, glucagon-like peptide-1 (GLP-1) analogue invented and developed by Novo Nordisk. It is the main ingredient in Wegovy, for overweight and obesity, as well as in Ozempic and Rybelsus for adults with type 2 diabetes. It has broad clinical recognition and approximately 38 million patient-years of use since launch.